

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Indications for which of the following PARP inhibitors, if any, were voluntarily withdrawn in the later-line setting for advanced ovarian cancer (OC)?
  - a. Olaparib
  - b. Niraparib
  - c. Rucaparib
  - d. All of the above
  - e. Later-line indications for none of these were voluntarily withdrawn
2. Which of the following best describes the target of the novel antibody-drug conjugate upifitamab rilsodotin, currently under investigation for OC?
  - a. Folate receptor alpha
  - b. NaPi2b
  - c. Tissue factor
  - d. TROP2
3. Tumor treating fields (TTFields) promote antitumor activity via which of the following mechanisms?
  - a. Disruption of cell migration
  - b. Enhancement of antitumor immunity
  - c. Interference with mitosis
  - d. Increased membrane permeability
  - e. All of the above
4. Based on promising early phase findings, an ongoing Phase III study is evaluating TTFields in combination with which of the following therapies for patients with recurrent OC?
  - a. Paclitaxel
  - b. Bevacizumab
  - c. Olaparib
  - d. Dostarlimab
  - e. Pembrolizumab
5. Based on Phase III data, which of the following types of adverse events of special interest is most commonly observed in patients receiving mirvetuximab soravtansine for platinum-resistant OC?
  - a. Dermatologic
  - b. Neurologic
  - c. Ocular
  - d. Respiratory